These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
639 related articles for article (PubMed ID: 17042762)
1. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Klaus J; Herrmann D; Breitkreutz I; Hegenbart U; Mazitschek U; Egerer G; Cremer FW; Lowenthal RM; Huesing J; Fruehauf S; Moehler T; Ho AD; Goldschmidt H Eur J Haematol; 2007 Jan; 78(1):21-8. PubMed ID: 17042762 [TBL] [Abstract][Full Text] [Related]
2. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma. Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297 [TBL] [Abstract][Full Text] [Related]
3. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome. Patriarca F; Damiani D; Fanin R; Grimaz S; Geromin A; Cerno M; Sperotto A; Silvestri F; Zaja F; Baccarani M Haematologica; 2000 Mar; 85(3):269-74. PubMed ID: 10702815 [TBL] [Abstract][Full Text] [Related]
4. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Kiss JE; Rybka WB; Winkelstein A; deMagalhaes-Silverman M; Lister J; D'Andrea P; Ball ED Bone Marrow Transplant; 1997 Feb; 19(4):303-10. PubMed ID: 9051238 [TBL] [Abstract][Full Text] [Related]
5. CXCR4 expression on transplanted peripheral blood CD34+ cells: relationship to engraftment after autologous transplantation in a cohort of multiple myeloma patients. Hicks C; Isaacs A; Wong R; Chong BH Ann Hematol; 2011 May; 90(5):547-55. PubMed ID: 20957366 [TBL] [Abstract][Full Text] [Related]
6. Subsets of CD34+ hematopoietic progenitors and platelet recovery after high dose chemotherapy and peripheral blood stem cell transplantation. Meldgaard Knudsen L; Jensen L; Jarlbaek L; Hansen PG; Hansen SW; Drivsholm L; Nikolaisen K; Gaarsdal E; Johnsen HE Haematologica; 1999 Jun; 84(6):517-24. PubMed ID: 10366795 [TBL] [Abstract][Full Text] [Related]
7. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Hiwase DK; Bollard G; Hiwase S; Bailey M; Muirhead J; Schwarer AP Cytotherapy; 2007; 9(6):539-47. PubMed ID: 17882718 [TBL] [Abstract][Full Text] [Related]
8. [Kinetics of hematopoiesis after high-dose chemotherapy and autologous peripheral stem cell transplantation]. Mayer J; Korístek Z; Pospísil Z; Vásová I; Adam Z; Hájek R; Krejcí M; Král Z; Navrátil M; Vorlícek J; Bourková L; Matýsková M; Adler J; Vinklárková J; Klabusay M; Koutná I; Hoffová V; Schmitzová D; Janovská E Cas Lek Cesk; 1999 Mar; 138(6):170-7. PubMed ID: 10510531 [TBL] [Abstract][Full Text] [Related]
9. Ideal body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss. Maclean PS; Parker AN; McQuaker IG; Clark AD; Farrell E; Douglas KW Bone Marrow Transplant; 2007 Oct; 40(7):665-9. PubMed ID: 17646841 [TBL] [Abstract][Full Text] [Related]
10. [The impact of CD34(+) cells and T cells subsets in grafts on prognosis of HLA-identical sibling allogeneic peripheral blood stem cell transplantation]. Zhou Z; Wang M; He Y Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):819-23. PubMed ID: 19176036 [TBL] [Abstract][Full Text] [Related]
11. Post-thaw viable CD34(+) cell count is a valuable predictor of haematopoietic stem cell engraftment in autologous peripheral blood stem cell transplantation. Lee S; Kim S; Kim H; Baek EJ; Jin H; Kim J; Kim HO Vox Sang; 2008 Feb; 94(2):146-52. PubMed ID: 18028260 [TBL] [Abstract][Full Text] [Related]
12. [Autologous peripheral blood selected CD34+ cell transplantation in the treatment of multiple myeloma]. Tang X; Morineau N; Milpied N; Moreau P; Bataille R; Harousseau JL Zhonghua Xue Ye Xue Za Zhi; 2001 Jul; 22(7):370-3. PubMed ID: 11877101 [TBL] [Abstract][Full Text] [Related]
13. CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients. Kasow KA; Sims-Poston L; Eldridge P; Hale GA Biol Blood Marrow Transplant; 2007 May; 13(5):608-14. PubMed ID: 17448921 [TBL] [Abstract][Full Text] [Related]
14. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593 [TBL] [Abstract][Full Text] [Related]
15. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Allan DS; Keeney M; Howson-Jan K; Popma J; Weir K; Bhatia M; Sutherland DR; Chin-Yee IH Bone Marrow Transplant; 2002 Jun; 29(12):967-72. PubMed ID: 12098064 [TBL] [Abstract][Full Text] [Related]
16. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968 [TBL] [Abstract][Full Text] [Related]